[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"ORIGIO, Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":117},{"warningLetters":4,"total":116},[5,31,53,76,97],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":27,"delivery_method":28,"recipient_title":19,"reference_number":29,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},21668,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-10-13T04:00:00Z\">10\u002F13\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-02T04:00:00Z\">10\u002F02\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Foriginalccouk-739334-10022026\">originalc.co.uk\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2602440\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>originalc.co.uk\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>United Kingdom\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@originalc.co.uk\"> sales@originalc.co.uk  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 2, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Foriginalc.co.uk and determined that e-liquid products listed there are offered for sale or distribution to consumers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901 of the FD&amp;C Act (21 U.S.C. § 387a) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act. Under section 906(d)(5) of the FD&amp;C Act (21 U.S.C. § 387f(d)(5)), it is unlawful for any retailer\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> to sell a tobacco product to any person younger than 21 years of age.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> This includes tobacco products containing nicotine from any source including cigarettes, smokeless tobacco, cigars, e-cigarettes, and nicotine pouches.\u003C\u002Fp>\u003Cp>\u003Cstrong>Tobacco Product Sold by a Retailer to an Individual Under the Age of 21 is Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 903(a)(7)(B) of the FD&amp;C Act (21 U.S.C. § 387c(a)(7)(B)), tobacco products are misbranded if sold or distributed by any retailer to a person younger than 21 years of age in violation of section 906(d)(5) of the FD&amp;C Act (21 U.S.C. § 387f(d)(5)). FDA has determined that your Cherry Bomb E-Liquid (Original Cirro Recipe) 18mg e-liquid product is misbranded under section 903(a)(7)(B) of the FD&amp;C Act (21 U.S.C. § 387c(a)(7)(B)) because this product was sold to a person younger than 21 years of age. Specifically, during FDA’s investigation of https:\u002F\u002Foriginalc.co.uk, a person younger than 21 years of age purchased the Cherry Bomb E-Liquid (Original Cirro Recipe) 18mg e-liquid product from your website.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and FDA’s implementing regulations, including those in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>Please be aware that the FD&amp;C Act requires “new tobacco products” to have premarket authorization. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007. See Section 910(a) of the FD&amp;C Act. For a list of all products that have been authorized by the FDA and certain others that may be legally marketed, please visit the Searchable Tobacco Products Database: https:\u002F\u002Fwww.fda.gov\u002Fsearchtobacco.\u003C\u002Fp>\u003Cp>You should take prompt action to address the violations that are referenced above, as well as any violations of the FD&amp;C Act and FDA’s implementing regulations that are the same as or similar to the ones stated above, and take any necessary actions to bring all your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at https:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, RW2602440, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Jill Atencio\u003Cbr>Acting Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\u003Cp>\u003Cstrong>VIA Electronic Mail\u003C\u002Fstrong>\u003Cbr>cc:\u003Cbr>Shopify, Inc.\u003Cbr>abuse@shopify.com\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Effective April 14, 2022, an amendment to the FD&amp;C Act extends FDA’s regulation of tobacco products to those containing nicotine from any source. For more information, please see, https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The term 'retailer' means any person, government, or entity who sells tobacco products to individuals for personal consumption, or who operates a facility where self-service displays of tobacco products are permitted. Section 900(14) of the FD&amp;C Act (21 U.S.C. § 387(14)).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Effective December 20, 2019, an amendment to the FD&amp;C Act raises the minimum age of sale of tobacco products to age 21. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fretail-sales-tobacco-products\u002Ftobacco-21.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\nRW2602440\n\nProduct:\n\nTobacco\n\nRecipient:\n\noriginalc.co.uk\n\nUnited Kingdom\n\nsales@originalc.co.uk\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nOctober 2, 2026\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Foriginalc.co.uk and determined that e-liquid products listed there are offered for sale or distribution to consumers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption.1 Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901 of the FD&C Act (21 U.S.C. § 387a) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act. Under section 906(d)(5) of the FD&C Act (21 U.S.C. § 387f(d)(5)), it is unlawful for any retailer2 to sell a tobacco product to any person younger than 21 years of age.3 This includes tobacco products containing nicotine from any source including cigarettes, smokeless tobacco, cigars, e-cigarettes, and nicotine pouches.\nTobacco Product Sold by a Retailer to an Individual Under the Age of 21 is Misbranded\nUnder section 903(a)(7)(B) of the FD&C Act (21 U.S.C. § 387c(a)(7)(B)), tobacco products are misbranded if sold or distributed by any retailer to a person younger than 21 years of age in violation of section 906(d)(5) of the FD&C Act (21 U.S.C. § 387f(d)(5)). FDA has determined that your Cherry Bomb E-Liquid (Original Cirro Recipe) 18mg e-liquid product is misbranded under section 903(a)(7)(B) of the FD&C Act (21 U.S.C. § 387c(a)(7)(B)) because this product was sold to a person younger than 21 years of age. Specifically, during FDA’s investigation of https:\u002F\u002Foriginalc.co.uk, a person younger than 21 years of age purchased the Cherry Bomb E-Liquid (Original Cirro Recipe) 18mg e-liquid product from your website.\nConclusion and Requested Actions\nIt is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and FDA’s implementing regulations, including those in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\nPlease be aware that the FD&C Act requires “new tobacco products” to have premarket authorization. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007. See Section 910(a) of the FD&C Act. For a list of all products that have been authorized by the FDA and certain others that may be legally marketed, please visit the Searchable Tobacco Products Database: https:\u002F\u002Fwww.fda.gov\u002Fsearchtobacco.\nYou should take prompt action to address the violations that are referenced above, as well as any violations of the FD&C Act and FDA’s implementing regulations that are the same as or similar to the ones stated above, and take any necessary actions to bring all your tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at https:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, RW2602440, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\nDPAL-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJill Atencio\nActing Director\nOffice of Compliance and Enforcement\nCenter for Tobacco Products\nVIA Electronic Mail\ncc:\nShopify, Inc.\nabuse@shopify.com\n______________________\n1 Effective April 14, 2022, an amendment to the FD&C Act extends FDA’s regulation of tobacco products to those containing nicotine from any source. For more information, please see, https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n2 The term 'retailer' means any person, government, or entity who sells tobacco products to individuals for personal consumption, or who operates a facility where self-service displays of tobacco products are permitted. Section 900(14) of the FD&C Act (21 U.S.C. § 387(14)).\n3 Effective December 20, 2019, an amendment to the FD&C Act raises the minimum age of sale of tobacco products to age 21. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fretail-sales-tobacco-products\u002Ftobacco-21.","originalc.co.uk","originalccouk-739334-10022026","2026-10-14T12:31:16.41489+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Foriginalccouk-739334-10022026","2026-11-17T01:02:03.701861+00:00","Warning Letter","Issued","2026-10-13","739334","Tobacco","2026-10-14T12:32:16.944+00:00","VIA Electronic Mail","RW2602440","2026-10-02",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":28,"recipient_title":19,"reference_number":51,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},1166,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2024-11-19T14:20:00Z\">11\u002F19\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-11-07T05:00:00Z\">11\u002F07\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Foriginitalia-srl-687935-11072024\">Originitalia SRL\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-12\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Pietro Giulio Orso\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Originitalia SRL\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Vicolo Don Antonio Menin 6\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>36030\u003C\u002Fspan> \u003Cspan>Caldogno\u003C\u002Fspan> \u003Cspan>VI\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Italy\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-12\u003C\u002Fp>\n\n\u003Cp>November 7, 2024\u003Cbr>\n\u003Cbr>\nDear Mr. Orso:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Originitalia SRL, FEI 3004420738, located at Vicolo Don Antonio Menin 6, Caldogno, Vicenza, 36030, Italy, from May 20 to 24, 2024.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your June 13, 2024 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP. You stated that as a result of the findings and necessary adjustments needed, you “announce the freezing of OTC production for the year 2024.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to test your incoming active pharmaceutical ingredients (API) for identity prior to manufacturing your bulk over-the counter (OTC) drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, you relied on certificates of analysis (COAs) from your suppliers to use incoming API without establishing the reliability of the specifications and characteristics of each supplier’s COAs.\u003Cbr>\n\u003Cbr>\nIdentity testing for each component lot used in drug product manufacturing is required, and you may only rely on COAs for other component attributes by validating the suppliers’ test results at appropriate intervals.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\n\t\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to perform adequate release testing for each batch of your drug product prior to distribution to the U.S. Market. You released your OTC drug product \u003Cstrong>(b)(4)\u003C\u002Fstrong>, without assay testing of the active ingredient, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>During the inspection, you stated that your firm did not perform any API assay testing of either bulk or finished products for the products released between 2022 and 2023. The assay test was performed in 2024 using reserve samples.\u003C\u002Fp>\n\n\u003Cp>Drug product batches must be tested for identity, strength, quality, and purity prior to release. Testing is an essential part of ensuring that the drug products you manufacture conform to all predetermined quality attributes, including microbiological specifications and are appropriate for their intended use. Without adequate testing, you lack basic data to support that each drug product batch conforms to appropriate specifications before release and distribution.\u003Cbr>\n\u003Cbr>\nIn response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\n\t\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>\n&nbsp; &nbsp; o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to validate your manufacturing processes for your OTC drug products and provide assurance that you are capable of consistently manufacturing a drug product with defined quality attributes.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\n\n\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>See the FDA's guidance for industry, \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>Additionally, you have not established evidence to show that your cleaning processes for your equipment are adequate to prevent product contamination. You also did not perform \u003Cstrong>(b)(4)\u003C\u002Fstrong> system qualification.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\n\t\u003Cli>A timeline for performing appropriate PPQ for each of your marketed drug products.\u003C\u002Fli>\n\t\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\n\t\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\n\t\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Drugs with higher toxicities\u003Cbr>\n&nbsp; &nbsp; o Drugs with higher drug potencies\u003Cbr>\n&nbsp; &nbsp; o Drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; &nbsp; o Drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\n\t\u003Cli>A procedure for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system monitoring that specifies routine microbial testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm did not have adequate stability data to demonstrate that the chemical and microbiological properties of your drug products met established specifications and remain acceptable throughout their shelf-life.\u003C\u002Fp>\n\n\u003Cp>Without appropriate stability studies, you do not have scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Stability-indicating methods.\u003Cbr>\n&nbsp; &nbsp; o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>\n&nbsp; &nbsp; o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\u003Cbr>\n&nbsp; &nbsp; o Detailed definition of the specific attributes to be tested at each station (timepoint).\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cem>Ineffective Quality System\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production, laboratory operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed products offered for import into the United States from your firm on Import Alert 66-40 on October 1, 2024.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Originitalia SRL, located at Vicolo Don Antonio Menin 6, Caldogno, Vicenza, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B) and are misbranded under section 502 of the FD&amp;C Act, respectively.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004420738 and ATTN: Chhaya Shetty.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-25-12\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Pietro Giulio Orso\n\nRecipient Title\n\nManaging Director\n\nOriginitalia SRL\n\nVicolo Don Antonio Menin 6\n\n36030 Caldogno VI\n\nItaly\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-12\n\nNovember 7, 2024\n\nDear Mr. Orso:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Originitalia SRL, FEI 3004420738, located at Vicolo Don Antonio Menin 6, Caldogno, Vicenza, 36030, Italy, from May 20 to 24, 2024.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your June 13, 2024 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP. You stated that as a result of the findings and necessary adjustments needed, you “announce the freezing of OTC production for the year 2024.”\n\n1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYou failed to test your incoming active pharmaceutical ingredients (API) for identity prior to manufacturing your bulk over-the counter (OTC) drug products, including (b)(4). Additionally, you relied on certificates of analysis (COAs) from your suppliers to use incoming API without establishing the reliability of the specifications and characteristics of each supplier’s COAs.\n\nIdentity testing for each component lot used in drug product manufacturing is required, and you may only rely on COAs for other component attributes by validating the suppliers’ test results at appropriate intervals.\n\nIn response to this letter, provide the following:\n\nA comprehensive review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\n\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n\n2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\n\nYou failed to perform adequate release testing for each batch of your drug product prior to distribution to the U.S. Market. You released your OTC drug product (b)(4), without assay testing of the active ingredient, (b)(4).\n\nDuring the inspection, you stated that your firm did not perform any API assay testing of either bulk or finished products for the products released between 2022 and 2023. The assay test was performed in 2024 using reserve samples.\n\nDrug product batches must be tested for identity, strength, quality, and purity prior to release. Testing is an essential part of ensuring that the drug products you manufacture conform to all predetermined quality attributes, including microbiological specifications and are appropriate for their intended use. Without adequate testing, you lack basic data to support that each drug product batch conforms to appropriate specifications before release and distribution.\n\nIn response to this letter, provide the following:\n\nA comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\nA list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\n\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a).\n\nYou failed to validate your manufacturing processes for your OTC drug products and provide assurance that you are capable of consistently manufacturing a drug product with defined quality attributes.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\n\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nSee the FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\nAdditionally, you have not established evidence to show that your cleaning processes for your equipment are adequate to prevent product contamination. You also did not perform (b)(4) system qualification.\n\nIn response to this letter, provide the following:\n\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\nA timeline for performing appropriate PPQ for each of your marketed drug products.\n\nProcess performance protocol(s), and written procedures for qualification of equipment and facilities.\n\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\n\no Drugs with higher toxicities\n\no Drugs with higher drug potencies\n\no Drugs of lower solubility in their cleaning solvents\n\no Drugs with characteristics that make them difficult to clean\n\no Swabbing locations for areas that are most difficult to clean\n\no Maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\nA summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\nA procedure for your (b)(4) system monitoring that specifies routine microbial testing of (b)(4) to ensure its acceptability for use in each batch of drug products produced by your firm.\n\n4. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\n\nYour firm did not have adequate stability data to demonstrate that the chemical and microbiological properties of your drug products met established specifications and remain acceptable throughout their shelf-life.\n\nWithout appropriate stability studies, you do not have scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\n\nIn response to this letter, provide the following:\n\nA comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability-indicating methods.\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\n\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\n\no Detailed definition of the specific attributes to be tested at each station (timepoint).\n\nAll procedures that describe these and other elements of your remediated stability program.\n\nIneffective Quality System\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production, laboratory operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\n\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nDrug Production Ceased\n\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed products offered for import into the United States from your firm on Import Alert 66-40 on October 1, 2024.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Originitalia SRL, located at Vicolo Don Antonio Menin 6, Caldogno, Vicenza, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B) and are misbranded under section 502 of the FD&C Act, respectively.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004420738 and ATTN: Chhaya Shetty.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research","Originitalia SRL","originitalia-srl-687935-11072024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Foriginitalia-srl-687935-11072024","2026-10-26T08:09:39.226459+00:00","2024-11-19","687935","Drugs","Mr. Pietro Giulio Orso","2026-08-19T18:45:31.783+00:00","320-25-12","2024-11-07",{"id":54,"raw":55,"subject":61,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":19,"letter_url":67,"updated_at":68,"action_type":22,"case_status":23,"posted_date":69,"marcs_cms_no":70,"product_type":71,"closeout_date":19,"issuing_office":59,"recipient_name":72,"body_fetched_at":73,"delivery_method":74,"recipient_title":19,"reference_number":19,"action_taken_date":75,"medical_device_id":19,"response_letter_date":19},76,[56,57,58,59,60,13,13,13],"\u003Ctime datetime=\"2026-06-23T04:00:00Z\">06\u002F23\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-23T04:00:00Z\">04\u002F23\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-imports-origins-728463-04232026\">Global Imports Origins \u003C\u002Fa>","Office of Inspections and Investigations","Foreign Supplier Verification Program (FSVP)\u003Cbr \u002F>\r\n","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Yi An\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Global Imports Origins \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9800 Centre Pkwy Ste 830\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Houston\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77036-8261\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Inspections and Investigations\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>4\u002F23\u002F2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS # 728463\u003C\u002Fp>\u003Cp>Dear Mr.Yi An:\u003C\u002Fp>\u003Cp>On March 3, 2026, through March 12, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Global Imports Origins located at 9800 Centre Pkwy Ste 830 Houston, TX 770036-8261. We also conducted an inspection on April 17, 2023, through May 5, 2023. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the following foods you import: Red Pepper (Mixed Vegetables) imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\u003C\u002Fp>\u003Cp>We have not received your response to the Form FDA 483a issued on March 12, 2026.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR1.502(a). Specifically, you did not develop an FSVP for the Red Pepper (Mixed Vegetables) imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementation regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Iris C. Tan, Compliance Officer, 9777 Via de las Amistad, Suite 131, San Diego, CA 92154. If you have any questions regarding this letter, you may contact Iris C. Tan via email at iris.tan@fda.hhs.gov. Please reference CMS #728463 on any documents or records you provide to us and\u002F or on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Todd Cato\u003Cbr>Director, Southwest Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nYi An\n\nRecipient Title\n\nOwner\n\nGlobal Imports Origins\n\n9800 Centre Pkwy Ste 830\n\nHouston, TX 77036-8261\n\nUnited States\n\nIssuing Office:\n\nOffice of Inspections and Investigations\n\nUnited States\n\n4\u002F23\u002F2026\nWARNING LETTER\nRe: CMS # 728463\nDear Mr.Yi An:\nOn March 3, 2026, through March 12, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Global Imports Origins located at 9800 Centre Pkwy Ste 830 Houston, TX 770036-8261. We also conducted an inspection on April 17, 2023, through May 5, 2023. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the following foods you import: Red Pepper (Mixed Vegetables) imported from (b)(4).\nBecause of these significant violations, you are not in compliance with section 805 of the FD&C Act.\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\nWe have not received your response to the Form FDA 483a issued on March 12, 2026.\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR1.502(a). Specifically, you did not develop an FSVP for the Red Pepper (Mixed Vegetables) imported from (b)(4), located in (b)(4).\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementation regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Iris C. Tan, Compliance Officer, 9777 Via de las Amistad, Suite 131, San Diego, CA 92154. If you have any questions regarding this letter, you may contact Iris C. Tan via email at iris.tan@fda.hhs.gov. Please reference CMS #728463 on any documents or records you provide to us and\u002F or on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nTodd Cato\nDirector, Southwest Imports","Global Imports Origins","global-imports-origins-728463-04232026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-imports-origins-728463-04232026","2026-10-26T08:08:46.507241+00:00","2026-06-23","728463","Food & Beverages","Yi An","2026-08-19T04:33:04.549+00:00","Via Express Delivery","2026-04-23",{"id":77,"raw":78,"subject":82,"body_html":83,"body_text":84,"firm_name":85,"letter_id":86,"created_at":87,"fei_number":19,"letter_url":88,"updated_at":89,"action_type":22,"case_status":23,"posted_date":90,"marcs_cms_no":91,"product_type":92,"closeout_date":19,"issuing_office":37,"recipient_name":93,"body_fetched_at":94,"delivery_method":28,"recipient_title":19,"reference_number":95,"action_taken_date":96,"medical_device_id":19,"response_letter_date":19},838,[79,80,81,37,82,13,13,13],"\u003Ctime datetime=\"2025-06-10T04:00:00Z\">06\u002F10\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-05-29T04:00:00Z\">05\u002F29\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famish-origins-management-llc-704166-05292025\">Amish Origins Management, LLC\u003C\u002Fa>","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-77\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Joshua V. Hansen\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Amish Origins Management, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1214 South Flat Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Worland\u003C\u002Fspan>, \u003Cspan>WY\u003C\u002Fspan> \u003Cspan>82401-9539\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-25-77\u003C\u002Fp>\u003Cp>May 29, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Hansen:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Amish Origins Management, LLC, FEI 3013538760, at 1214 South Flat Road, Worland, from January 7 to 10, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Your AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). In addition, your AMISH ORIGINS AUTHENTIC LIP DOC SPF 15 MEDICATED is misbranded under 502(f)(2) of the FD&amp;C Act, 21 U.S.C. 352(f)(2), and is further misbranded along with your AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>We reviewed your February 1, 2025 response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cu>CGMP Violations\u003C\u002Fu>\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing, as necessary (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to conduct adequate release testing of all your drug products prior to distribution. Specifically, you did not test your drug products for identity, assay, impurities, or microbiological attributes.\u003C\u002Fp>\u003Cp>In your response, you state that you are now performing release testing. Your response is inadequate because you failed to adequately detail the tests, methods, and specifications for your over-the-counter (OTC) drug products to ensure your finished products meets appropriate standards prior to release and distribution.\u003C\u002Fp>\u003Cp>Full release testing, including strength and identity testing of the active ingredient, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to assure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003Cbr>• A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003Cbr>&nbsp; o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>&nbsp; o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to perform adequate identity testing of each component lot used in the manufacture of your OTC drug products, including for your active ingredient menthol and glycerin. Additionally, you relied on your suppliers’ certificates of analyses (COAs) without establishing the reliability of each of your suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\u003Cp>\u003Cem>Glycerin\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately test each shipment of each lot of glycerin for identity, a component at higher risk for diethylene glycol (DEG) and ethylene glycol (EG) contamination. Identity testing for glycerin and certain other high-risk drug components\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform adequate identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of this component for use in manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response, you commit to inspecting and testing materials upon arrival and to creating a procedure for supplier qualification. Your response is inadequate. You did not provide a detailed plan for how your components will be tested, including test methods and review of compendial requirements, or a timeline for implementing the proposed corrective actions. Further, you did not consider a retrospective review of previously distributed OTC drug products, or details on how suppliers will be qualified.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have appropriate assurance that components conform to appropriate specifications prior to use in the drug products you manufacture.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product lots for the presence of DEG and EG.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, propylene glycol). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPAs that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\u003Cli>The chemical and microbiology quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to document the manufacturing instructions for your OTC drug products and did not have any executed batch records for distributed drug products.\u003C\u002Fp>\u003Cp>In your response, you state that, “recipes and procedures have been followed for decades. Though not in writing, they have been committed to memory.” You also state that you hired an employee responsible for observing and documenting every step of production. Your response is inadequate because you did not provide adequate details or supportive documentation and did not consider a retrospective evaluation of your products currently on the market.\u003C\u002Fp>\u003Cp>Complete and accurate batch production and control records are necessary to ensure that manufacturing processes are consistently followed and reproducible. Incomplete manufacturing records deprive you of the ability to ensure the batches are formulated to provide not less than 100% of the labeled amount of active ingredient.\u003C\u002Fp>\u003Cp>In response to this letter, provide examples of batch production and control records your firm will use moving forward that include all elements required per 21 CFR 211.188. These should include, but not limited to, an accurate reproduction of the appropriate master batch record, which is checked for accuracy, dated, and signed; and documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures OTC topical analgesic drug products. Your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, you failed to have written procedures in place governing manufacturing and quality oversight.\u003C\u002Fp>\u003Cp>In your response, while you acknowledge that your responsibilities and procedures were not in writing, you do not provide specific procedures or timelines for implementing your proposed CAPAs.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003Cbr>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>&nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>&nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>&nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>&nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003Cbr>• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fp>\u003Cp>\u003Cu>External Analgesics Unapproved New Drug Violations\u003C\u002Fu>\u003C\u002Fp>\u003Cp>AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe are drugs as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples of claims observed on the AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe product labels that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>“AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray”\u003Cbr>“\u003Cstrong>Drug Facts…Purpose\u003C\u002Fstrong>…Topical Analgesic…\u003Cstrong>Uses\u003C\u002Fstrong>…temporarily relieves minor aches and pains associated with ▪ Arthritis Pain ▪ Sore Joints and Muscles ▪ Coughs ▪ Sore Throat ▪ Sinus Trouble ▪ Bruises ▪ Minor Burns ▪ Insect Bites ▪ Dry or Chapped Hands and feet” [from your product label]\u003C\u002Fp>\u003Cp>“AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment”\u003Cbr>“\u003Cstrong>Drug Facts…Purpose\u003C\u002Fstrong>…Topical Analgesic…\u003Cstrong>Uses\u003C\u002Fstrong>…temporarily relieves minor aches and pains associated with ▪Arthritis Pain ▪ Sore Joints and Muscles ▪ Coughs ▪ Sore Throat ▪ Sinus Trouble ▪ Bruises ▪ Minor Burns ▪ Insect Bites ▪ Dry or Chapped Hands and feet” [from your product label]\u003C\u002Fp>\u003Cp>“AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream”\u003Cbr>“\u003Cstrong>Drug Facts…Purpose\u003C\u002Fstrong>…Topical Analgesic…\u003Cstrong>Uses\u003C\u002Fstrong>…temporarily relieves minor aches and pains associated with ▪Arthritis Pain ▪ Sore Joints and Muscles ▪ Sore Throat ▪ Sinus Trouble ▪ Restless Leg Syndrome” [from your product label]\u003C\u002Fp>\u003Cp>“AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe”\u003Cbr>“\u003Cstrong>Drug Facts…Purpose\u003C\u002Fstrong>…Topical Analgesic…\u003Cstrong>Uses\u003C\u002Fstrong>…temporarily relieves minor aches and pains associated with ▪Arthritis Pain ▪ Sore Joints and Muscles ▪ Coughs ▪ Sore Throat ▪ Sinus Trouble ▪ Bruises ▪ Minor Burns ▪ Insect Bites ▪ Dry or Chapped Hands and Feet” [from your product label]\u003C\u002Fp>\u003Cp>Based on the above labeling claims AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe are intended for use as over-the-counter (OTC) external analgesic drug products. As described below, the drug products AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless it is lawfully marketed under section 505G of the FD&amp;C Act. No FDA approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for these drug products identified above.\u003C\u002Fp>\u003Cp>Your AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe are external analgesic drug products subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to OTC external analgesic drug products, such drug products are addressed in “Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use” (hereafter M017).\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe do not conform to the conditions specified in the final administrative order for the reasons described below.\u003C\u002Fp>\u003Cp>Your AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe drug products include indications that do not comply with the indications permitted for over-the-counter external analgesic drug products. For example, the labels include claims to relieves minor aches and pains associated with colds, coughs, restless legs, sore throat, sinus trouble, and dry or chapped hands and feet for AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment. In addition, the label for AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream includes claims to relieves minor aches and pains associated sore throat, sinus trouble, and restless leg syndrome. Furthermore, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe includes claims to relieves minor aches and pains associated with coughs, sore throat, sinus trouble, and dry or chapped hands and feet. These indications described above go beyond the general intended uses for an external analgesic drug product as stated in M017.\u003C\u002Fp>\u003Cp>Thus, as labeled, your AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe products do not comply with the applicable final administrative order described above or any other final order.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Moreover, there is no evident basis under the FD&amp;C Act under which these products would be legally marketed without an approved application. Thus, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). There are no FDA-approved applications in effect for your drug products, accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a).\u003C\u002Fp>\u003Cp>Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\u003Cp>\u003Cu>External Analgesics Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Additionally, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cu>Sunscreen Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fp>\u003Cp>AMISH ORIGINS AUTHENTIC LIP DOC SPF 15 MEDICATED is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as an OTC sunscreen drug product addressed in “Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use.”\u003C\u002Fp>\u003Cp>Examples of claims observed on the AMISH ORIGINS AUTHENTIC LIP DOC SPF 15 MEDICATED product label and labeling from your website and social media sites listed above provide evidence of the intended use (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>“AMISH ORIGINS AUTHENTIC LIP DOC SPF 15 MEDICATED”\u003Cbr>&nbsp; “\u003Cstrong>Uses\u003C\u002Fstrong>: Helps prevent sunburn …\u003Cstrong>Drug Facts…Purpose\u003C\u002Fstrong>…Sunscreen” [from your product labels]\u003C\u002Fp>\u003Cp>Your AMISH ORIGINS AUTHENTIC LIP DOC SPF 15 MEDICATED product misbranded under section 502(f)(2) of the FD&amp;C Act because its labeling does not “[bear]…such adequate warnings against use in those pathological conditions or by children where its use may be dangerous to health, or against unsafe dosage or methods or duration of administration or application, in such manner and form, as are necessary for the protection of users…”. Here, the warning described in the product labeling fails to bear all of the required warnings for sunscreen drug products described in M020.50(d)(1)(i) and (ii) “Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use”. Specifically, your product fails to disclose the required warnings, “Do not use on damaged or broken skin,” and “keep out of eyes.”\u003C\u002Fp>\u003Cp>Additionally, your AMISH ORIGINS AUTHENTIC LIP DOC SPF 15 MEDICATED product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section (as described above) and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. We note that under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\u003C\u002Fp>\u003Cp>We also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&amp;C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>After you receive this letter, respond to this office in writing within 15 working days. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices, and\u002For submit a request to schedule an FDA inspection.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3013538760 and ATTN: Christina Capacci-Daniel.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Components with higher risk of DEG or EG contamination compared to other drug components.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(1) of the FD&amp;C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs;\" notably, conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR 330 prior to enactment of the CARES Act. In the case of external analgesic drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use. See Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe products are GRASE for use under the conditions prescribed, recommended, or suggested in its labeling.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-25-77\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Joshua V. Hansen\n\nRecipient Title\n\nPresident\n\nAmish Origins Management, LLC\n\n1214 South Flat Road\n\nWorland, WY 82401-9539\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-77\nMay 29, 2025\nDear Mr. Hansen:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Amish Origins Management, LLC, FEI 3013538760, at 1214 South Flat Road, Worland, from January 7 to 10, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nYour AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). In addition, your AMISH ORIGINS AUTHENTIC LIP DOC SPF 15 MEDICATED is misbranded under 502(f)(2) of the FD&C Act, 21 U.S.C. 352(f)(2), and is further misbranded along with your AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\nWe reviewed your February 1, 2025 response to our Form FDA 483 in detail.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\nCGMP Violations\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing, as necessary (21 CFR 211.165(a) and 211.165(b)).\nYour firm failed to conduct adequate release testing of all your drug products prior to distribution. Specifically, you did not test your drug products for identity, assay, impurities, or microbiological attributes.\nIn your response, you state that you are now performing release testing. Your response is inadequate because you failed to adequately detail the tests, methods, and specifications for your over-the-counter (OTC) drug products to ensure your finished products meets appropriate standards prior to release and distribution.\nFull release testing, including strength and identity testing of the active ingredient, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to assure that your drug products conform to appropriate specifications before release.\nIn response to this letter, provide:\n• A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYou failed to perform adequate identity testing of each component lot used in the manufacture of your OTC drug products, including for your active ingredient menthol and glycerin. Additionally, you relied on your suppliers’ certificates of analyses (COAs) without establishing the reliability of each of your suppliers’ test analyses at appropriate intervals.\nGlycerin\nYou failed to adequately test each shipment of each lot of glycerin for identity, a component at higher risk for diethylene glycol (DEG) and ethylene glycol (EG) contamination. Identity testing for glycerin and certain other high-risk drug components1 includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform adequate identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of this component for use in manufacture of your drug products.\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\nIn your response, you commit to inspecting and testing materials upon arrival and to creating a procedure for supplier qualification. Your response is inadequate. You did not provide a detailed plan for how your components will be tested, including test methods and review of compendial requirements, or a timeline for implementing the proposed corrective actions. Further, you did not consider a retrospective review of previously distributed OTC drug products, or details on how suppliers will be qualified.\nWithout adequate testing, you do not have appropriate assurance that components conform to appropriate specifications prior to use in the drug products you manufacture.\nIn response to this letter, provide:\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product lots for the presence of DEG and EG.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, propylene glycol). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPAs that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\nThe chemical and microbiology quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n3. Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).\nYou failed to document the manufacturing instructions for your OTC drug products and did not have any executed batch records for distributed drug products.\nIn your response, you state that, “recipes and procedures have been followed for decades. Though not in writing, they have been committed to memory.” You also state that you hired an employee responsible for observing and documenting every step of production. Your response is inadequate because you did not provide adequate details or supportive documentation and did not consider a retrospective evaluation of your products currently on the market.\nComplete and accurate batch production and control records are necessary to ensure that manufacturing processes are consistently followed and reproducible. Incomplete manufacturing records deprive you of the ability to ensure the batches are formulated to provide not less than 100% of the labeled amount of active ingredient.\nIn response to this letter, provide examples of batch production and control records your firm will use moving forward that include all elements required per 21 CFR 211.188. These should include, but not limited to, an accurate reproduction of the appropriate master batch record, which is checked for accuracy, dated, and signed; and documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished.\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour firm manufactures OTC topical analgesic drug products. Your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, you failed to have written procedures in place governing manufacturing and quality oversight.\nIn your response, while you acknowledge that your responsibilities and procedures were not in writing, you do not provide specific procedures or timelines for implementing your proposed CAPAs.\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn response to this letter, provide:\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nExternal Analgesics Unapproved New Drug Violations\nAMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe are drugs as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples of claims observed on the AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe product labels that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\n“AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray”\n“Drug Facts…Purpose…Topical Analgesic…Uses…temporarily relieves minor aches and pains associated with ▪ Arthritis Pain ▪ Sore Joints and Muscles ▪ Coughs ▪ Sore Throat ▪ Sinus Trouble ▪ Bruises ▪ Minor Burns ▪ Insect Bites ▪ Dry or Chapped Hands and feet” [from your product label]\n“AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment”\n“Drug Facts…Purpose…Topical Analgesic…Uses…temporarily relieves minor aches and pains associated with ▪Arthritis Pain ▪ Sore Joints and Muscles ▪ Coughs ▪ Sore Throat ▪ Sinus Trouble ▪ Bruises ▪ Minor Burns ▪ Insect Bites ▪ Dry or Chapped Hands and feet” [from your product label]\n“AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream”\n“Drug Facts…Purpose…Topical Analgesic…Uses…temporarily relieves minor aches and pains associated with ▪Arthritis Pain ▪ Sore Joints and Muscles ▪ Sore Throat ▪ Sinus Trouble ▪ Restless Leg Syndrome” [from your product label]\n“AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe”\n“Drug Facts…Purpose…Topical Analgesic…Uses…temporarily relieves minor aches and pains associated with ▪Arthritis Pain ▪ Sore Joints and Muscles ▪ Coughs ▪ Sore Throat ▪ Sinus Trouble ▪ Bruises ▪ Minor Burns ▪ Insect Bites ▪ Dry or Chapped Hands and Feet” [from your product label]\nBased on the above labeling claims AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe are intended for use as over-the-counter (OTC) external analgesic drug products. As described below, the drug products AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless it is lawfully marketed under section 505G of the FD&C Act. No FDA approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for these drug products identified above.\nYour AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe are external analgesic drug products subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to OTC external analgesic drug products, such drug products are addressed in “Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use” (hereafter M017).2 However AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe do not conform to the conditions specified in the final administrative order for the reasons described below.\nYour AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe drug products include indications that do not comply with the indications permitted for over-the-counter external analgesic drug products. For example, the labels include claims to relieves minor aches and pains associated with colds, coughs, restless legs, sore throat, sinus trouble, and dry or chapped hands and feet for AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment. In addition, the label for AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream includes claims to relieves minor aches and pains associated sore throat, sinus trouble, and restless leg syndrome. Furthermore, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe includes claims to relieves minor aches and pains associated with coughs, sore throat, sinus trouble, and dry or chapped hands and feet. These indications described above go beyond the general intended uses for an external analgesic drug product as stated in M017.\nThus, as labeled, your AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe products do not comply with the applicable final administrative order described above or any other final order.3 Moreover, there is no evident basis under the FD&C Act under which these products would be legally marketed without an approved application. Thus, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). There are no FDA-approved applications in effect for your drug products, accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a).\nIntroduction or delivery for introduction of such a product into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\nExternal Analgesics Misbranded Drug Violations\nAdditionally, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nSunscreen Misbranded Drug Violations\nAMISH ORIGINS AUTHENTIC LIP DOC SPF 15 MEDICATED is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as an OTC sunscreen drug product addressed in “Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use.”\nExamples of claims observed on the AMISH ORIGINS AUTHENTIC LIP DOC SPF 15 MEDICATED product label and labeling from your website and social media sites listed above provide evidence of the intended use (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n“AMISH ORIGINS AUTHENTIC LIP DOC SPF 15 MEDICATED”\n“Uses: Helps prevent sunburn …Drug Facts…Purpose…Sunscreen” [from your product labels]\nYour AMISH ORIGINS AUTHENTIC LIP DOC SPF 15 MEDICATED product misbranded under section 502(f)(2) of the FD&C Act because its labeling does not “[bear]…such adequate warnings against use in those pathological conditions or by children where its use may be dangerous to health, or against unsafe dosage or methods or duration of administration or application, in such manner and form, as are necessary for the protection of users…”. Here, the warning described in the product labeling fails to bear all of the required warnings for sunscreen drug products described in M020.50(d)(1)(i) and (ii) “Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use”. Specifically, your product fails to disclose the required warnings, “Do not use on damaged or broken skin,” and “keep out of eyes.”\nAdditionally, your AMISH ORIGINS AUTHENTIC LIP DOC SPF 15 MEDICATED product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section (as described above) and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nCosmetics Manufactured for Distribution in the United States\nIn addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. We note that under section 301(a) of the FD&C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\nWe also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nAfter you receive this letter, respond to this office in writing within 15 working days. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices, and\u002For submit a request to schedule an FDA inspection.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3013538760 and ATTN: Christina Capacci-Daniel.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\u002FS\u002F\nTina Smith\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_______________________\n1 Components with higher risk of DEG or EG contamination compared to other drug components.\n2 Section 505G(a)(1) of the FD&C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs;\" notably, conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR 330 prior to enactment of the CARES Act. In the case of external analgesic drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use. See Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F.\n3 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe products are GRASE for use under the conditions prescribed, recommended, or suggested in its labeling.","Amish Origins Management, LLC","amish-origins-management-llc-704166-05292025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famish-origins-management-llc-704166-05292025","2026-10-26T08:07:55.230833+00:00","2025-06-10","704166","Drugs Over-the-Counter Drugs","Mr. Joshua V. Hansen","2026-08-19T16:41:02.722+00:00","320-25-77","2025-05-29",{"id":98,"raw":99,"subject":104,"body_html":105,"body_text":106,"firm_name":107,"letter_id":108,"created_at":18,"fei_number":19,"letter_url":109,"updated_at":110,"action_type":22,"case_status":23,"posted_date":111,"marcs_cms_no":112,"product_type":71,"closeout_date":19,"issuing_office":103,"recipient_name":113,"body_fetched_at":114,"delivery_method":28,"recipient_title":19,"reference_number":19,"action_taken_date":115,"medical_device_id":19,"response_letter_date":19},21713,[100,101,102,103,104,13,13,13],"\u003Ctime datetime=\"2026-09-29T04:00:00Z\">09\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-06T05:00:00Z\">03\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmiddlefield-original-cheese-cooperative-719761-03062026\">Middlefield Original Cheese Cooperative\u003C\u002Fa>","Human Foods Program","CGMP\u002FManufacturing, Packing or Holding Human Food\u002FAdulterated\u002FInsanitary Conditions","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Nevin R. Byler\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Middlefield Original Cheese Cooperative\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>16942 Kinsman Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Middlefield\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>44062\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Sunrisecreamery@plainconnect.com\"> Sunrisecreamery@plainconnect.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 6, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS # 719761\u003C\u002Fp>\u003Cp>Dear Mr. Byler:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your ready-to-eat (RTE) human food manufacturing facility, located at 16942 Kinsman Rd Middlefield, OH 44062 on August 12, 2025, through September 8, 2025. This inspection was initiated as a follow-up to a voluntary recall your firm conducted of cheese products due to your findings of pathogenic \u003Cem>Listeria monocytogenes (L. monocytogenes)\u003C\u002Fem> in cheese manufactured by your facility.\u003C\u002Fp>\u003Cp>During the inspection of your facility, FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food Regulations (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). Additionally, FDA collected environmental samples (i.e., swabs) from various areas in your processing facility. FDA laboratory analyses of the environmental swabs found the presences of \u003Cem>L. monocytogenes\u003C\u002Fem>, a human pathogen, in your facility.\u003C\u002Fp>\u003Cp>Based on FDA’s inspectional findings and analytical results for samples collected from your production environment, we have determined that the RTE cheese products manufactured in your facility are adulterated within the meaning section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)] in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP &amp; PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and FDA’s regulations through links on FDA’s homepage at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, FDA issued an FDA Form 483 (FDA-483), Inspectional Observations, listing deviations found at your facility. On September 17, 2025, we received your firm’s responses to the FDA-483 via email, describing corrective actions taken and planned by your firm. Based on our review of the inspectional findings and the responses that you provided, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your facility.\u003Cbr>We discuss your responses below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Hazard Analysis and Risk-Based Preventive Controls Requirements (21 CFR Part 117, Subpart C)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>1. You did not implement preventive controls in your food safety plan to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented and the food manufactured, processed, packed, or held by your facility will not be adulterated under section 402 of the Act, as required by 21 CFR 117.135(a)(1).\u003C\u002Fp>\u003Cp>Specifically, your hazard analysis for your various cheese products identifies the hazard of contamination with environmental pathogens such as “Bacterial Pathogens” such as Listeria, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Salmonella, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and\u002For \u003Cstrong>(b)(4)\u003C\u002Fstrong> as requiring a preventive control at the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” steps. Your sanitation preventive controls indicate that environmental monitoring is to be performed \u003Cstrong>(b)(4)\u003C\u002Fstrong>, sanitizer chemical concentrations are to be tested \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspections are to be performed \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, FDA Investigators observed the following instances in which you failed to implement your procedures:\u003C\u002Fp>\u003Cp>a. A review of your records revealed that you had not conducted environmental monitoring during the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This is a repeat deviation from the previous FDA inspection conducted on September 18, 2023 through September 27, 2023 during which it was observed you did not implement \u003Cstrong>(b)(4)\u003C\u002Fstrong> environmental monitoring activities as required by your environmental monitoring program.\u003C\u002Fp>\u003Cp>b. A review of your records revealed that you failed to test the concentration of your \u003Cstrong>(b)(4) \u003C\u002Fstrong>sanitizer during the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This \u003Cstrong>(b)(4)\u003C\u002Fstrong> sanitizer is used \u003Cstrong>(b)(4)\u003C\u002Fstrong> to sanitize your cheese processing equipment \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Furthermore, preventive controls are subject to preventive control management components (monitoring, corrective actions and corrections, and verification) as appropriate to ensure the effectiveness of the preventive controls, taking into account the nature of the preventive control and its role in the facility’s food safety system (see 21 CFR 117.140). We note that you did not have adequate controls in place for contamination with environmental pathogens regarding monitoring, corrective action and verification activities, as evidenced by the following observations during the inspection:\u003C\u002Fp>\u003Cp>c. A review of your environmental monitoring records revealed positive findings of \u003Cem>L. monocytogenes\u003C\u002Fem> in your facility on \u003Cstrong>(b)(4)\u003C\u002Fstrong> and again in repeat locations beginning on \u003Cstrong>(b)(4)\u003C\u002Fstrong> through \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The repeat positive findings collected from the same locations indicate that your current corrective action strategy of cleaning, sanitizing, and re-swabbing until achieving negative results is inadequate for controlling environmental pathogens in your facility.\u003C\u002Fp>\u003Cp>d. FDA Investigators collected an environmental sample from your facility on August 12, 2025 during the manufacturing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cheese. The sample consisted of 80 environmental swabs collected from various surfaces in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> room, which resulted in the finding of 14 positive swabs for \u003Cem>L. monocytogenes\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>e. Your written environmental monitoring program, dated January 9, 2023, specifies the “corrective action for environmental monitoring positive listeria” for “Zone \u003Cstrong>(b)(4)\u003C\u002Fstrong>” is to “…Clean equipment and resample for Listeria…”, “…Reclean and resample until negative sample” and “Conduct retraining for employee Sanitation.” However, your environmental monitoring program is inadequate because it does not include a procedure for determining the root cause of contamination and does not address product disposition after a positive result is reported, as required by 21 CFR 117.150(a)(2).\u003C\u002Fp>\u003Cp>f. The FDA investigators observed equipment in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> room which lacked an adequately cleanable design which creates a food contamination risk. Specifically, the metal surfaces surrounding the underside of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> were corroded and pieces of metal flaked off upon touching the surface.\u003C\u002Fp>\u003Cp>Your September 17, 2025 response identified the root cause of the \u003Cem>L. monocytogenes\u003C\u002Fem> finding in the plant as “…\u003Cstrong>(b)(4)\u003C\u002Fstrong>…” and “…\u003Cstrong>(b)(4)\u003C\u002Fstrong>…” and states that you took the corrective actions of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your response does not identify the source of the \u003Cem>L. monocytogenes\u003C\u002Fem> or include any evidence that an investigation was conducted to determine the source of contamination. Your response also does not include evidence to demonstrate that the referenced actions have been completed such as the updated environmental monitoring program, cleaning\u002Fsanitation procedures, corresponding monitoring records, and photographic evidence or a detailed description of what was cleaned and sanitized and how the tasks were completed to demonstrate the facility and equipment repairs were made. Furthermore, your response included a laboratory report, dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>, capturing environmental monitoring results for \u003Cstrong>(b)(4)\u003C\u002Fstrong> swab sub-samples collected on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. One collection of \u003Cstrong>(b)(4) \u003C\u002Fstrong>environmental swabs is not representative of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> square foot facility as it does not provide adequate assurance that the \u003Cem>L. monocytogenes\u003C\u002Fem> found in your facility has been eliminated from the processing environment based on the severity of the findings in the environment and in finished product.\u003C\u002Fp>\u003Cp>2. You did not review your process preventive control monitoring and verification records, as required by 21 CFR 117.165(a)(4).\u003C\u002Fp>\u003Cp>Specifically:\u003Cbr>a. From January 2025 through July 2025, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> sanitation forms for the \u003Cstrong>(b)(4) \u003C\u002Fstrong>production room, plant packaging area, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> room repeatedly lacked a signature, or included a signature with no date, to indicate who reviewed the records and when.\u003C\u002Fp>\u003Cp>b. From \u003Cstrong>(b)(4)\u003C\u002Fstrong> through \u003Cstrong>(b)(4)\u003C\u002Fstrong> your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning log lacked dates for record review.\u003C\u002Fp>\u003Cp>c. From April 2025 through August 2025, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> “chemical concentration logs” lacked signatures capturing review. Your chemical concentration logs capture concentrations for detergents and sanitizers used for cleaning and sanitizing the manufacturing environment and equipment.\u003C\u002Fp>\u003Cp>d. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> test results for January 2, 2025, through August 19, 2025, lacked signatures or dates to indicate the results were reviewed. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> records capture the testing for the presence of antibiotic residues for your incoming raw milk.\u003C\u002Fp>\u003Cp>e. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> pasteurizer time and temperature monitoring charts contained review signatures but lacked review dates for charts dated \u003Cstrong>(b)(4) \u003C\u002Fstrong>and \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>f. Your metal detector verification log lacked signatures or dates to indicate the logs were reviewed between \u003Cstrong>(b)(4)\u003C\u002Fstrong> through \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>This is a repeat deviation from the previous FDA inspection conducted on September 18, 2023 through September 27, 2023 which was discussed relating to the failure to consistently review your monitoring records.\u003C\u002Fp>\u003Cp>Your September 17, 2025 response states the root cause for the lack of monitoring and review of the preventive controls was “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” with the corrective action of “…\u003Cstrong>(b)(4)\u003C\u002Fstrong>…”. Your response lacks evidence to demonstrate that the preventive controls are being adequately implemented, and the management components are being reviewed by \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>3. For your RTE cheese products, your written recall plan does not describe the steps to be taken to directly notify the direct consignees of the food being recalled, including how to return or dispose of the affected food, or to notify the public about any hazard presented by the food when appropriate to protect public health, as required by 21 CFR 117.139(b). Furthermore, there are no assigned responsibilities for the individuals listed as part of the recall team to perform the above-mentioned actions. Your RTE cheese products have multiple known or reasonably foreseeable hazards requiring preventive controls (see 21 CFR § 117.139(a). On July 21, 2025, your facility initiated a recall of multiple cheese products due to positive results for \u003Cem>L. monocytogenes\u003C\u002Fem> in a sample of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cheese product which your facility collected. On August 27, 2025, your facility initiated a second recall due to additional cheese samples testing positive for \u003Cem>L. monocytogenes\u003C\u002Fem> which your facility also collected.\u003C\u002Fp>\u003Cp>This is a repeat deviation from the previous FDA inspection conducted on September 18, 2023, through September 27, 2023 which was discussed relating to your recall plan lacking steps to notify consignees of a recall and assigning responsibilities for such steps.\u003C\u002Fp>\u003Cp>Your September 17, 2025 response identifies the root cause for the inadequate recall plan as “…\u003Cstrong>(b)(4)\u003C\u002Fstrong>” with a resolution of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, this response is not complete because it does not include a recall plan with updated procedures and assigned responsibilities for those implementing them.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Current Good Manufacturing Practice Requirements (21 CFR Part 117, Subpart B)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>4. You did not take effective measures to exclude pests from the manufacturing, processing, packing, and holding areas and to protect against the contamination of food on the premises by pests, as required by 21 CFR 117.35(c).\u003C\u002Fp>\u003Cp>Specifically, on August 12, 2025, an FDA Investigator observed one live apparent cockroach on the end of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> table. On August 28, 2025, they observed two live apparent cockroaches in electrical boxes on the wall next to the pasteurizer, three apparent live cockroaches under the edge of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, one dead apparent cockroach on the floor next to \u003Cstrong>(b)(4)\u003C\u002Fstrong> vat \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and one live apparent cockroach on its back in the bottom of \u003Cstrong>(b)(4)\u003C\u002Fstrong> vat \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which is a food contact surface. On August 13, 2025, the investigator observed approximately 12 apparent rodent excreta pellets and ants, too numerous to count, on the floor of the employee break room. Your employee breakroom is approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> feet down the hall from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> production room and close to product storage cooler \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your September 17, 2025 response indicates that you \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and states that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> “…has an effective program…”. However, no evidence was provided to demonstrate the effectiveness of your corrective action.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct any violations. Failure to adequately address these violations may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Daniel Johnson, Compliance Officer, Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Daniel Johnson via email at: Daniel.Johnson@fda.hhs.gov Please include reference CMS #719761 on any submissions and within the subject line of any email correspondence to the agency.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD, MBA\u003Cbr>Acting Director\u003Cbr>Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Nevin R. Byler\n\nRecipient Title\n\nManager\n\nMiddlefield Original Cheese Cooperative\n\n16942 Kinsman Rd\n\nMiddlefield, OH 44062\n\nUnited States\n\nSunrisecreamery@plainconnect.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nMarch 6, 2026\nWARNING LETTER\nRe: CMS # 719761\nDear Mr. Byler:\nThe United States Food and Drug Administration (FDA) inspected your ready-to-eat (RTE) human food manufacturing facility, located at 16942 Kinsman Rd Middlefield, OH 44062 on August 12, 2025, through September 8, 2025. This inspection was initiated as a follow-up to a voluntary recall your firm conducted of cheese products due to your findings of pathogenic Listeria monocytogenes (L. monocytogenes) in cheese manufactured by your facility.\nDuring the inspection of your facility, FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food Regulations (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). Additionally, FDA collected environmental samples (i.e., swabs) from various areas in your processing facility. FDA laboratory analyses of the environmental swabs found the presences of L. monocytogenes, a human pathogen, in your facility.\nBased on FDA’s inspectional findings and analytical results for samples collected from your production environment, we have determined that the RTE cheese products manufactured in your facility are adulterated within the meaning section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)] in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and FDA’s regulations through links on FDA’s homepage at www.fda.gov.\nAt the conclusion of the inspection, FDA issued an FDA Form 483 (FDA-483), Inspectional Observations, listing deviations found at your facility. On September 17, 2025, we received your firm’s responses to the FDA-483 via email, describing corrective actions taken and planned by your firm. Based on our review of the inspectional findings and the responses that you provided, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your facility.\nWe discuss your responses below.\nHazard Analysis and Risk-Based Preventive Controls Requirements (21 CFR Part 117, Subpart C)\n1. You did not implement preventive controls in your food safety plan to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented and the food manufactured, processed, packed, or held by your facility will not be adulterated under section 402 of the Act, as required by 21 CFR 117.135(a)(1).\nSpecifically, your hazard analysis for your various cheese products identifies the hazard of contamination with environmental pathogens such as “Bacterial Pathogens” such as Listeria, (b)(4). Salmonella, (b)(4), and\u002For (b)(4) as requiring a preventive control at the “(b)(4)” and the “(b)(4)” steps. Your sanitation preventive controls indicate that environmental monitoring is to be performed (b)(4), sanitizer chemical concentrations are to be tested (b)(4), and (b)(4) inspections are to be performed (b)(4). However, FDA Investigators observed the following instances in which you failed to implement your procedures:\na. A review of your records revealed that you had not conducted environmental monitoring during the (b)(4) of (b)(4). This is a repeat deviation from the previous FDA inspection conducted on September 18, 2023 through September 27, 2023 during which it was observed you did not implement (b)(4) environmental monitoring activities as required by your environmental monitoring program.\nb. A review of your records revealed that you failed to test the concentration of your (b)(4) sanitizer during the (b)(4). This (b)(4) sanitizer is used (b)(4) to sanitize your cheese processing equipment (b)(4).\nFurthermore, preventive controls are subject to preventive control management components (monitoring, corrective actions and corrections, and verification) as appropriate to ensure the effectiveness of the preventive controls, taking into account the nature of the preventive control and its role in the facility’s food safety system (see 21 CFR 117.140). We note that you did not have adequate controls in place for contamination with environmental pathogens regarding monitoring, corrective action and verification activities, as evidenced by the following observations during the inspection:\nc. A review of your environmental monitoring records revealed positive findings of L. monocytogenes in your facility on (b)(4) and again in repeat locations beginning on (b)(4) through (b)(4). The repeat positive findings collected from the same locations indicate that your current corrective action strategy of cleaning, sanitizing, and re-swabbing until achieving negative results is inadequate for controlling environmental pathogens in your facility.\nd. FDA Investigators collected an environmental sample from your facility on August 12, 2025 during the manufacturing of (b)(4) cheese. The sample consisted of 80 environmental swabs collected from various surfaces in your (b)(4) room, which resulted in the finding of 14 positive swabs for L. monocytogenes.\ne. Your written environmental monitoring program, dated January 9, 2023, specifies the “corrective action for environmental monitoring positive listeria” for “Zone (b)(4)” is to “…Clean equipment and resample for Listeria…”, “…Reclean and resample until negative sample” and “Conduct retraining for employee Sanitation.” However, your environmental monitoring program is inadequate because it does not include a procedure for determining the root cause of contamination and does not address product disposition after a positive result is reported, as required by 21 CFR 117.150(a)(2).\nf. The FDA investigators observed equipment in your (b)(4) room which lacked an adequately cleanable design which creates a food contamination risk. Specifically, the metal surfaces surrounding the underside of the (b)(4) were corroded and pieces of metal flaked off upon touching the surface.\nYour September 17, 2025 response identified the root cause of the L. monocytogenes finding in the plant as “…(b)(4)…” and “…(b)(4)…” and states that you took the corrective actions of (b)(4). However, your response does not identify the source of the L. monocytogenes or include any evidence that an investigation was conducted to determine the source of contamination. Your response also does not include evidence to demonstrate that the referenced actions have been completed such as the updated environmental monitoring program, cleaning\u002Fsanitation procedures, corresponding monitoring records, and photographic evidence or a detailed description of what was cleaned and sanitized and how the tasks were completed to demonstrate the facility and equipment repairs were made. Furthermore, your response included a laboratory report, dated (b)(4), capturing environmental monitoring results for (b)(4) swab sub-samples collected on (b)(4). One collection of (b)(4) environmental swabs is not representative of a (b)(4) square foot facility as it does not provide adequate assurance that the L. monocytogenes found in your facility has been eliminated from the processing environment based on the severity of the findings in the environment and in finished product.\n2. You did not review your process preventive control monitoring and verification records, as required by 21 CFR 117.165(a)(4).\nSpecifically:\na. From January 2025 through July 2025, your (b)(4) sanitation forms for the (b)(4) production room, plant packaging area, and (b)(4) room repeatedly lacked a signature, or included a signature with no date, to indicate who reviewed the records and when.\nb. From (b)(4) through (b)(4) your (b)(4) cleaning log lacked dates for record review.\nc. From April 2025 through August 2025, your (b)(4) “chemical concentration logs” lacked signatures capturing review. Your chemical concentration logs capture concentrations for detergents and sanitizers used for cleaning and sanitizing the manufacturing environment and equipment.\nd. Your (b)(4) test results for January 2, 2025, through August 19, 2025, lacked signatures or dates to indicate the results were reviewed. Your (b)(4) records capture the testing for the presence of antibiotic residues for your incoming raw milk.\ne. Your (b)(4) pasteurizer time and temperature monitoring charts contained review signatures but lacked review dates for charts dated (b)(4) and (b)(4) and (b)(4).\nf. Your metal detector verification log lacked signatures or dates to indicate the logs were reviewed between (b)(4) through (b)(4).\nThis is a repeat deviation from the previous FDA inspection conducted on September 18, 2023 through September 27, 2023 which was discussed relating to the failure to consistently review your monitoring records.\nYour September 17, 2025 response states the root cause for the lack of monitoring and review of the preventive controls was “(b)(4)” with the corrective action of “…(b)(4)…”. Your response lacks evidence to demonstrate that the preventive controls are being adequately implemented, and the management components are being reviewed by (b)(4).\n3. For your RTE cheese products, your written recall plan does not describe the steps to be taken to directly notify the direct consignees of the food being recalled, including how to return or dispose of the affected food, or to notify the public about any hazard presented by the food when appropriate to protect public health, as required by 21 CFR 117.139(b). Furthermore, there are no assigned responsibilities for the individuals listed as part of the recall team to perform the above-mentioned actions. Your RTE cheese products have multiple known or reasonably foreseeable hazards requiring preventive controls (see 21 CFR § 117.139(a). On July 21, 2025, your facility initiated a recall of multiple cheese products due to positive results for L. monocytogenes in a sample of (b)(4) cheese product which your facility collected. On August 27, 2025, your facility initiated a second recall due to additional cheese samples testing positive for L. monocytogenes which your facility also collected.\nThis is a repeat deviation from the previous FDA inspection conducted on September 18, 2023, through September 27, 2023 which was discussed relating to your recall plan lacking steps to notify consignees of a recall and assigning responsibilities for such steps.\nYour September 17, 2025 response identifies the root cause for the inadequate recall plan as “…(b)(4)” with a resolution of “(b)(4).” However, this response is not complete because it does not include a recall plan with updated procedures and assigned responsibilities for those implementing them.\nCurrent Good Manufacturing Practice Requirements (21 CFR Part 117, Subpart B)\n4. You did not take effective measures to exclude pests from the manufacturing, processing, packing, and holding areas and to protect against the contamination of food on the premises by pests, as required by 21 CFR 117.35(c).\nSpecifically, on August 12, 2025, an FDA Investigator observed one live apparent cockroach on the end of a (b)(4) table. On August 28, 2025, they observed two live apparent cockroaches in electrical boxes on the wall next to the pasteurizer, three apparent live cockroaches under the edge of the (b)(4), one dead apparent cockroach on the floor next to (b)(4) vat (b)(4), and one live apparent cockroach on its back in the bottom of (b)(4) vat (b)(4), which is a food contact surface. On August 13, 2025, the investigator observed approximately 12 apparent rodent excreta pellets and ants, too numerous to count, on the floor of the employee break room. Your employee breakroom is approximately (b)(4) feet down the hall from the (b)(4) production room and close to product storage cooler (b)(4).\nYour September 17, 2025 response indicates that you (b)(4), and states that the (b)(4) “…has an effective program…”. However, no evidence was provided to demonstrate the effectiveness of your corrective action.\nThis letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct any violations. Failure to adequately address these violations may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nPlease send your reply to the Food and Drug Administration, Attention: Daniel Johnson, Compliance Officer, Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Daniel Johnson via email at: Daniel.Johnson@fda.hhs.gov Please include reference CMS #719761 on any submissions and within the subject line of any email correspondence to the agency.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD, MBA\nActing Director\nOffice of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Middlefield Original Cheese Cooperative","middlefield-original-cheese-cooperative-719761-03062026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmiddlefield-original-cheese-cooperative-719761-03062026","2026-11-10T01:02:16.121874+00:00","2026-09-29","719761","Mr. Nevin R. Byler","2026-10-14T12:35:12.707+00:00","2026-03-06",5,{"510k":118,"classification":119,"enforcement":120,"event":121,"event_backfill":122,"pma":123,"warning_letter":124},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]